Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism.

Autor: Gudula J A M Boon, Nienke van Rein, Harm Jan Bogaard, Yvonne M Ende-Verhaar, Menno V Huisman, Lucia J M Kroft, Felix J M van der Meer, Lilian J Meijboom, Petr Symersky, Anton Vonk Noordegraaf, Frederikus A Klok

Publikováno v: PLoS ONE, Vol 15, Iss 4, p e0232354 (2020)

BACKGROUND:The pathophysiology of chronic thromboembolic pulmonary hypertension (CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher risk of CTEPH after acute pulmonary embolism (PE), partly explaining the transiti

Externí odkaz: https://doaj.org/article/da4df8c485b54ad8a92d586bb3bedf18

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.

Autor: Nienke van Rein, Willem M Lijfering, Mettine H A Bos, Martien H Herruer, Helga W Vermaas, Felix J M van der Meer, Pieter H Reitsma

Publikováno v: PLoS ONE, Vol 11, Iss 12, p e0164485 (2016)

Risk scores for patients who are at high risk for major bleeding complications during treatment with vitamin K antagonists (VKAs) do not perform that well. BLEEDS was initiated to search for new biomarkers that predict bleeding in these patients.To d

Externí odkaz: https://doaj.org/article/8e4556d104514dd691ba79eb7bb4ff79

Selective serotonin reuptake inhibitor use and risk of major bleeding during treatment with vitamin K antagonists

Autor: Johanna Louise I. Burggraaf, Sanne Bakker, Marieke J. H. A. Kruip, Felix J. M. van der Meer, Willem M. Lijfering, Nienke van Rein

Publikováno v: Thrombosis and Haemostasis, 123(2), 245-254. Georg Thieme Verlag

Background Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition. Aims To determine whether SSR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb4b2894bc500ea60839ad88f1f0c673
http://www.scopus.com/inward/record.url?scp=85140850419&partnerID=8YFLogxK

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial)

Autor: Iris van Moort, Tim Preijers, Laura H Bukkems, Hendrika C A M Hazendonk, Johanna G van der Bom, Britta A P Laros-van Gorkom, Erik A M Beckers, Laurens Nieuwenhuizen, Felix J M van der Meer, Paula Ypma, Michiel Coppens, Karin Fijnvandraat, Roger E G Schutgens, Karina Meijer, Frank W G Leebeek, Ron A A Mathôt, Marjon H Cnossen, Marjon H. Cnossen, Frank W.G. Leebeek, Ron A.A. Mathôt, Marieke J.H.A. Kruip, Suzanne Polinder, Janske Lock, Hendrika C.A.M. Hazendonk, Iris Van Moort, Jessica M. Heijdra, Marie C.H.J. Goedhart, Wala Al Arashi, Nico C.B. De Jager, Laura H. Bukkems, Michael E. Cloesmeijer, Alexander Janssen, Rienk Y.J. Tamminga, Paul Brons, Saskia E.M. Schols, Jeroen C.J. Eikenboom, Felix J.M. Van der Meer, Roger E.G. Schutgens, Kathelijne Fischer, Karin P.M. Van Galen, Erik E.A.M. Beckers, Floor C.J.I. Heubel-Moenen, Mariëtte H.E. Driessens, Ineke Van Vliet, Peter W. Collins, Ri Liesner, Pratima Chowdary, Carolyn M. Millar, Dan Hart, David Keeling

Publikováno v: The Lancet Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet. Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet Haematology, 8, e492-e502
Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
The Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
Lancet Haematology, 8, 7, pp. e492-e502

Contains fulltext : 237493.pdf (Publisher’s version ) (Closed access) BACKGROUND: Dosing of replacement therapy with factor VIII concentrate in patients with haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e090125dd5a4d36f53b9e9735c2c92
http://www.scopus.com/inward/record.url?scp=85108329665&partnerID=8YFLogxK

Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data

Autor: Felix J. M. van der Meer, Martine J Hollestelle, Piet Meijer

Publikováno v: Clinical Chemistry and Laboratory Medicine (CCLM). 58:1921-1930

Objectives Chromogenic anti-activated factor X (FXa) assays are currently the “gold standard” for monitoring indirect anticoagulants. However, anti-FXa has been shown to vary according to the choice of reagents. In the present study, the performa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa853255b024bf5e99a417c698a48db
https://doi.org/10.1515/cclm-2020-0130